{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:03:29Z","timestamp":1747177409949,"version":"3.40.5"},"reference-count":181,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Biomaterials Science, Polymer Edition"],"published-print":{"date-parts":[[2022,1,2]]},"DOI":"10.1080\/09205063.2021.1975020","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T19:06:32Z","timestamp":1630436792000},"page":"110-136","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Repurposing pharmaceutical excipients as an antiviral agent against SARS-CoV-2"],"prefix":"10.1080","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6412-6903","authenticated-orcid":false,"given":"Manisha","family":"Malani","sequence":"first","affiliation":[{"name":"Translational Pharmaceutics Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Hyderabad, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prerana","family":"Salunke","sequence":"additional","affiliation":[{"name":"Translational Pharmaceutics Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Hyderabad, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shraddha","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Translational Pharmaceutics Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Hyderabad, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaurav K.","family":"Jain","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Sciences, Delhi Pharmaceutical Sciences and Research University, New Delhi, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Afsana","family":"Sheikh","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0890-769X","authenticated-orcid":false,"given":"Prashant","family":"Kesharwani","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutics, School of Pharmaceutical Education and Research, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7864-6053","authenticated-orcid":false,"given":"Jayabalan","family":"Nirmal","sequence":"additional","affiliation":[{"name":"Translational Pharmaceutics Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science (BITS)-Pilani, Hyderabad, India;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,9,28]]},"reference":[{"key":"e_1_3_3_2_1","article-title":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle","author":"Lu H","unstructured":"Lu H, Stratton CW, Tang YW. Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle. J Med Virol.\u00a02020;92:401.","journal-title":"J Med Virol"},{"unstructured":"World Health Organization. Coronavirus disease 2019 (COVID-19) Situation Report \u2013 117. 2020.\u00a0Geneva Switzerland.","key":"e_1_3_3_3_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_4_1","DOI":"10.1001\/jama.2020.0757"},{"doi-asserted-by":"publisher","key":"e_1_3_3_5_1","DOI":"10.1126\/science.abb2507"},{"unstructured":"World Health Organization. Coronavirus. 2020. Available from: https:\/\/www.who.int\/health-topics\/coronavirus#tab=tab_1","key":"e_1_3_3_6_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_7_1","DOI":"10.1001\/jama.2020.1585"},{"key":"e_1_3_3_8_1","volume-title":"Global spread of coronavirus disease 2019 and malaria: an epidemiological paradox in the early stage of a pandemic","author":"Napoli PE","year":"2020","unstructured":"Napoli PE, Nioi M. Global spread of coronavirus disease 2019 and malaria: an epidemiological paradox in the early stage of a pandemic. Switzerland: Multidisciplinary Digital Publishing Institute; 2020."},{"unstructured":"ECfDPaCE. Q & A on novel coronavirus. Stockholm: ECDC; 2020. Available from: https:\/\/www.ecdc.europa.eu\/en\/novel-coronavirus-china\/questions-answers","key":"e_1_3_3_9_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_10_1","DOI":"10.2807\/1560-7917.ES.2020.25.5.2000062"},{"doi-asserted-by":"publisher","key":"e_1_3_3_11_1","DOI":"10.7326\/M20-0504"},{"doi-asserted-by":"publisher","key":"e_1_3_3_12_1","DOI":"10.1503\/cmaj.1040398"},{"doi-asserted-by":"publisher","key":"e_1_3_3_13_1","DOI":"10.1056\/NEJMc2001737"},{"key":"e_1_3_3_14_1","volume-title":"Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations: scientific brief, 27 March 2020","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Modes of transmission of virus causing COVID-19: implications for IPC precaution recommendations: scientific brief, 27 March 2020. Geneva: World Health Organization; 2020."},{"key":"e_1_3_3_15_1","volume-title":"The ocular surface and the coronavirus disease 2019: does a dual \u2018ocular route\u2019exist","author":"Napoli PE","year":"2020","unstructured":"Napoli PE, Nioi M, d\u2019Aloja E, et\u00a0al. The ocular surface and the coronavirus disease 2019: does a dual \u2018ocular route\u2019exist? Switzerland: Multidisciplinary Digital Publishing Institute; 2020."},{"doi-asserted-by":"publisher","key":"e_1_3_3_16_1","DOI":"10.3390\/jcm9082441"},{"doi-asserted-by":"publisher","key":"e_1_3_3_17_1","DOI":"10.3390\/jcm9051403"},{"doi-asserted-by":"publisher","key":"e_1_3_3_18_1","DOI":"10.1056\/NEJMoa2022483"},{"key":"e_1_3_3_19_1","article-title":"Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial","author":"Zhang Y-J","year":"2020","unstructured":"Zhang Y-J, Zeng G, Pan H-X, et\u00a0al. Immunogenicity and safety of a SARS-CoV-2 inactivated vaccine in healthy adults aged 18-59 years: report of the randomized, double-blind, and placebo-controlled phase 2 clinical trial. medRxiv. 2020.","journal-title":"medRxiv"},{"doi-asserted-by":"publisher","key":"e_1_3_3_20_1","DOI":"10.1016\/S0140-6736(20)31604-4"},{"unstructured":"Bharat Biotech. India\u2019s 1st COVID-19 Vaccine - COVAXIN\u2122. 2020. Available from: https:\/\/www.bharatbiotech.com\/images\/press\/Indias-1st-COVID-19-Vaccine-COVAXIN-Developed-by-Bharat-Biotech-gets-DCGI-approval-for-Phase-I-and-II-Human-Clinical-Trials.pdf","key":"e_1_3_3_21_1"},{"unstructured":"FDA. Pfizer vaccine. 2020. Available from: https:\/\/www.fda.gov\/media\/144412\/download","key":"e_1_3_3_22_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_23_1","DOI":"10.1056\/NEJMoa2035389"},{"doi-asserted-by":"publisher","key":"e_1_3_3_24_1","DOI":"10.1016\/S0140-6736(21)00947-8"},{"unstructured":"Phase BBA. Results of COVAXIN\u00ae: India\u2019s first COVID-19 vaccine demonstrates interim clinical efficacy of 81%. Covaxinphase 3-efficacy-results. pdf (bharatbiotech. com). https:\/\/www.bharatbiotech.com\/images\/press\/covaxin-phase3-efficacy-results.pdf","key":"e_1_3_3_25_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_26_1","DOI":"10.1016\/S0140-6736(21)00628-0"},{"doi-asserted-by":"publisher","key":"e_1_3_3_27_1","DOI":"10.1016\/S1473-3099(21)00330-3"},{"doi-asserted-by":"publisher","key":"e_1_3_3_28_1","DOI":"10.1016\/S0140-6736(21)00234-8"},{"unstructured":"ClinicalTrials.gov. A study to evaluate a range of dose levels and vaccination intervals of Ad26.COV2.S in healthy adults and adolescents. ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04535453","key":"e_1_3_3_29_1"},{"unstructured":"ClinicalTrials.gov. A study of Ad26.COV2.S for the prevention of SARS-CoV-2-mediated COVID-19 in adult participants (ENSEMBLE). ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04505722","key":"e_1_3_3_30_1"},{"unstructured":"ClinicalTrials.gov. A study to evaluate the safety reactogenicity and effectiveness of mRNA-1273 vaccine in adolescents 12 to <18 years old to prevent COVID-19 (TeenCove). ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04649151","key":"e_1_3_3_31_1"},{"unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy immune response and safety of a COVID-19 vaccine in adults \u2265 18 years with a pediatric expansion in adolescents (12 to < 18 years) at risk for SARS-CoV-2. ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04611802","key":"e_1_3_3_32_1"},{"unstructured":"ClinicalTrials.gov. Safety and immunogenicity of SARS-CoV-2 mRNA vaccine (BNT162b2) in Chinese healthy population. ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04649021","key":"e_1_3_3_33_1"},{"unstructured":"Sanofi Pasteur. Study of Recombinant Protein Vaccines With Adjuvant as a Primary Series and as a Booster Dose Against COVID-19 in Adults 18 Years of Age and Older (VAT00002). 2021.","key":"e_1_3_3_34_1"},{"unstructured":"ClinicalTrials.gov. Study of a recombinant coronavirus-like particle COVID-19 vaccine in adults. ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04636697","key":"e_1_3_3_35_1"},{"unstructured":"ClinicalTrials.gov. Safety immunogenicity and efficacy of INO-4800 for COVID-19 in healthy seronegative adults at high risk of SARS-CoV-2 exposure. ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04642638","key":"e_1_3_3_36_1"},{"unstructured":"ECT Register. COVID-19 A Phase II\/III randomized stratified observer-blind placebo-controlled study to evaluate the efficacy safety and immunogenicity of GRAd-COV2 vaccine in adults aged 18 years and older. EU Clinical Trials Register. 2021. Available from: https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2020-005915-39","key":"e_1_3_3_37_1"},{"unstructured":"ClinicalTrials.gov. A controlled phase 2\/3 study of adjuvanted recombinant SARS-CoV-2 trimeric S-protein vaccine (SCB-2019) for the prevention of COVID-19 (SCB-2019). ClinicalTrialsgov. 2021. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04672395","key":"e_1_3_3_38_1"},{"unstructured":"ClinicalTrials.gov. Favipiravir in hospitalized COVID-19 patients (FIC). 2020. Available from: https:\/\/clinicaltrialsgov\/ct2\/show\/NCT04359615","key":"e_1_3_3_39_1"},{"unstructured":"World Health Organisation. Q&A: dexamethasone and COVID-19. 2020. Available from: https:\/\/wwwwhoint\/emergencies\/diseases\/novel-coronavirus-2019\/question-and-answers-hub\/q-a-Detail\/q-a-dexamethasone-and-covid-19?gclid=Cj0KCQjw7ZL6BRCm ARIsAH6XFDKt_Glf3cqfI3CaRdCUrbnNogaT_WfnXUkiXra0YP9oS3XR5hAFtnUaAti AEALw_wcB","key":"e_1_3_3_40_1"},{"unstructured":"World Health Organisation. Coronavirus disease (COVID-19) advice for the public: mythbusters. 2020. Available from: https:\/\/wwwwhoint\/emergencies\/diseases\/novel-coronavirus-2019\/advice-for-public\/myth-busters?gclid=Cj0KCQjw7ZL6BRCmARIsAH6X FDL3ZZSd8f_QCkSSyYKQd9QnVefVJA4e_3SV8KQYtOE0g8wxrZami4caAl6REALw_wcB.#chloroquine","key":"e_1_3_3_41_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_42_1","DOI":"10.1016\/S0140-6736(20)30183-5"},{"issue":"1","key":"e_1_3_3_43_1","first-page":"3","article-title":"Properties of coronavirus and SARS-CoV-2","volume":"42","author":"Malik YA.","year":"2020","unstructured":"Malik YA. Properties of coronavirus and SARS-CoV-2. Malays J Pathol. 2020;42(1):3\u201311.","journal-title":"Malays J Pathol"},{"doi-asserted-by":"publisher","key":"e_1_3_3_44_1","DOI":"10.1016\/j.it.2020.03.007"},{"doi-asserted-by":"publisher","key":"e_1_3_3_45_1","DOI":"10.1038\/nrmicro2090"},{"doi-asserted-by":"publisher","key":"e_1_3_3_46_1","DOI":"10.1371\/journal.ppat.1007236"},{"doi-asserted-by":"publisher","key":"e_1_3_3_47_1","DOI":"10.1007\/978-1-4939-2438-7_1"},{"key":"e_1_3_3_48_1","first-page":"127","volume-title":"Coronavirus cis-acting RNA elements. Advances in virus research","author":"Madhugiri R","year":"2016","unstructured":"Madhugiri R, Fricke M, Marz M. Coronavirus cis-acting RNA elements. Advances in virus research. Vol. 96. Amsterdam, Netherlands: Elsevier; 2016. p. 127\u2013163."},{"doi-asserted-by":"publisher","key":"e_1_3_3_49_1","DOI":"10.1002\/jmv.25681"},{"doi-asserted-by":"publisher","key":"e_1_3_3_50_1","DOI":"10.1016\/j.cell.2020.02.052"},{"doi-asserted-by":"publisher","key":"e_1_3_3_51_1","DOI":"10.1128\/JVI.02062-10"},{"doi-asserted-by":"publisher","key":"e_1_3_3_52_1","DOI":"10.1016\/j.jare.2020.03.005"},{"doi-asserted-by":"crossref","unstructured":"V\u2019kovski P Kratzel A Steiner S Stalder H Thiel V. Coronavirus biology and replication: implications for SARS-CoV-2. Nature Reviews Microbiology . 2021;19(3):155\u201370.","key":"e_1_3_3_53_1","DOI":"10.1038\/s41579-020-00468-6"},{"doi-asserted-by":"publisher","key":"e_1_3_3_54_1","DOI":"10.1038\/s41569-020-0360-5"},{"doi-asserted-by":"publisher","key":"e_1_3_3_55_1","DOI":"10.1016\/S0140-6736(20)30628-0"},{"key":"e_1_3_3_56_1","volume-title":"Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics","author":"Talevi A","year":"2020","unstructured":"Talevi A, Bellera CL. Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. United Kingdom: Taylor & Francis; 2020."},{"doi-asserted-by":"publisher","key":"e_1_3_3_57_1","DOI":"10.1111\/bph.13798"},{"doi-asserted-by":"publisher","key":"e_1_3_3_58_1","DOI":"10.4103\/ijmr.IJMR_585_20"},{"key":"e_1_3_3_59_1","first-page":"161","volume-title":"Understanding biotechnology business models and managing risk. Biotechnology entrepreneurship","author":"Shimasaki C.","year":"2014","unstructured":"Shimasaki C. Understanding biotechnology business models and managing risk. Biotechnology entrepreneurship. Amsterdam, Netherlands: Elsevier; 2014. p. 161\u2013174."},{"doi-asserted-by":"publisher","key":"e_1_3_3_60_1","DOI":"10.1038\/nrd.2018.168"},{"unstructured":"Spencer M. Drug repurposing \u2013 harnessing the positive side effects of \u2018old school\u2019 drugs. MND Research Blog. 2019. Available from: https:\/\/mndresearch.blog\/2019\/03\/27\/drug-repurposing-harnessing-the-positive-side-effects-of-old-school-drugs\/.","key":"e_1_3_3_61_1"},{"key":"e_1_3_3_62_1","volume-title":"In search of COVID-19 treatments: the opportunities and challenges of using existing drugs","author":"Ali A.","year":"2020","unstructured":"Ali A. In search of COVID-19 treatments: the opportunities and challenges of using existing drugs. 2020."},{"doi-asserted-by":"publisher","key":"e_1_3_3_63_1","DOI":"10.1002\/9780470929353"},{"unstructured":"Foo W Peng T Chow K Mishra Y Stinsa L editors. Combating coronavirus: key role of cyclodextrins in treatment and prevention. 2020.","key":"e_1_3_3_64_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_65_1","DOI":"10.5582\/ddt.2020.01012"},{"doi-asserted-by":"publisher","key":"e_1_3_3_66_1","DOI":"10.1093\/ofid\/ofaa105"},{"doi-asserted-by":"publisher","key":"e_1_3_3_67_1","DOI":"10.1016\/j.ijantimicag.2020.105969"},{"unstructured":"Drugbank. Remdesivir. Drug Bank. 2020; Available from: https:\/\/go.drugbank.com\/drugs\/DB14761.","key":"e_1_3_3_68_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_69_1","DOI":"10.2183\/pjab.93.027"},{"unstructured":"RxList. WebMD. Available from: https:\/\/www.rxlist.com\/script\/main\/hp.asp","key":"e_1_3_3_70_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_71_1","DOI":"10.1016\/j.ijantimicag.2020.105938"},{"doi-asserted-by":"publisher","key":"e_1_3_3_72_1","DOI":"10.1002\/prp2.293"},{"doi-asserted-by":"publisher","key":"e_1_3_3_73_1","DOI":"10.1016\/j.ijantimicag.2020.106053"},{"unstructured":"FDA. SPRYCEL. 2009. Available from: www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/021986s004lbl.pdf","key":"e_1_3_3_74_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_75_1","DOI":"10.1128\/AAC.03036-14"},{"unstructured":"FDA. GLEEVEC. 2008. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/021588s024lbl.pdf","key":"e_1_3_3_76_1"},{"issue":"2","key":"e_1_3_3_77_1","first-page":"57","article-title":"Interaction between SArS-CoV-2 and human organism","volume":"63","author":"Pl\u0103cint\u0103 G","year":"2020","unstructured":"Pl\u0103cint\u0103 G, P\u00e2ntea V, Cojuhari L, et\u00a0al. Interaction between SArS-CoV-2 and human organism. Moldovan Med J. 2020;63(2):57\u201362.","journal-title":"Moldovan Med J"},{"doi-asserted-by":"publisher","key":"e_1_3_3_78_1","DOI":"10.1016\/j.reuma.2020.03.001"},{"doi-asserted-by":"publisher","key":"e_1_3_3_79_1","DOI":"10.1007\/s00296-020-04603-7"},{"key":"e_1_3_3_80_1","first-page":"276","article-title":"Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure?","volume":"24","author":"Cour M","year":"2020","unstructured":"Cour M, Ovize M, Argaud L. Cyclosporine A: a valid candidate to treat COVID-19 patients with acute respiratory failure? BioMed Central. 2020;24:276.","journal-title":"BioMed Central"},{"doi-asserted-by":"publisher","key":"e_1_3_3_81_1","DOI":"10.1016\/j.mehy.2020.110011"},{"key":"e_1_3_3_82_1","volume-title":"StatPearls","author":"Mann SK","year":"2019","unstructured":"Mann SK, Chlorpromazine MR. StatPearls [Internet]. Treasure Island, Florida: StatPearls Publishing; 2019."},{"doi-asserted-by":"crossref","unstructured":"Xu L Tong J Wu Y Zhao S Lin B-L. A computational evaluation of targeted oxidation strategy (TOS) for potential inhibition of SARS-CoV-2 by disulfiram and analogues. Biophys Chem. 2021;276:106610.","key":"e_1_3_3_83_1","DOI":"10.1016\/j.bpc.2021.106610"},{"doi-asserted-by":"crossref","unstructured":"Meneguzzo F Pagliaro M. Hydroxychloroquine for the Treatment of Coronavirus Disease 2019: Evidence Possible Mode of Action and Industrial Supply. Medicine Research. 2020;4(3):200014.","key":"e_1_3_3_84_1","DOI":"10.21127\/yaoyimr20200014"},{"key":"e_1_3_3_85_1","volume-title":"Small animal clinical pharmacology","author":"Maddison JE","year":"2008","unstructured":"Maddison JE, Page SW, Church DB. Small animal clinical pharmacology. Vol. 5. Amsterdam, Netherlands: Elsevier Health Sciences; 2008."},{"unstructured":"PubChem [Internet]. Bethesda (MD): National Library of Medicine (US) National Center for Biotechnology Information; 2004-. PubChem Compound Summary for CID 4413 Nafamostat; [cited 2021 Sept. 9]. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Nafamostat.","key":"e_1_3_3_86_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_87_1","DOI":"10.1128\/AAC.00754-20"},{"doi-asserted-by":"publisher","key":"e_1_3_3_88_1","DOI":"10.1016\/j.ijid.2020.05.072"},{"issue":"2","key":"e_1_3_3_89_1","first-page":"1","article-title":"TMPRSS2-inhibitors play a role in cell entry mechanism of COVID-19: an insight into camostat and nefamostat","volume":"2","author":"Bittmann S","year":"2020","unstructured":"Bittmann S, Luchter E, Weissenstein A, et\u00a0al. TMPRSS2-inhibitors play a role in cell entry mechanism of COVID-19: an insight into camostat and nefamostat. J Regen Biol Med. 2020;2(2):1\u20133.","journal-title":"J Regen Biol Med"},{"doi-asserted-by":"publisher","key":"e_1_3_3_90_1","DOI":"10.1073\/pnas.0403596101"},{"doi-asserted-by":"publisher","key":"e_1_3_3_91_1","DOI":"10.1056\/NEJMoa2001282"},{"issue":"4","key":"e_1_3_3_92_1","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/s41591-020-0849-9","article-title":"Lopinavir-ritonavir in severe COVID-19","volume":"26","author":"Stower H.","year":"2020","unstructured":"Stower H. Lopinavir-ritonavir in severe COVID-19. Nat Med. 2020;26(4):465.","journal-title":"Nat Med"},{"issue":"2","key":"e_1_3_3_93_1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4103\/bbrj.bbrj_53_20","article-title":"Tamoxifen from chemotherapy to antiviral drug: possible activity against COVID-19","volume":"4","author":"Almosawey HAS","year":"2020","unstructured":"Almosawey HAS, Al-Khikani FHO, Hameed RM, et\u00a0al. Tamoxifen from chemotherapy to antiviral drug: possible activity against COVID-19. Biomed Biotechnol Res J (BBRJ). 2020;4(2):108.","journal-title":"Biomed Biotechnol Res J (BBRJ"},{"doi-asserted-by":"publisher","key":"e_1_3_3_94_1","DOI":"10.3390\/v8120331"},{"doi-asserted-by":"publisher","key":"e_1_3_3_95_1","DOI":"10.31080\/ASMI.2020.03.0534"},{"doi-asserted-by":"publisher","key":"e_1_3_3_96_1","DOI":"10.1186\/s12916-020-01533-w"},{"doi-asserted-by":"publisher","key":"e_1_3_3_97_1","DOI":"10.1128\/JVI.02322-09"},{"doi-asserted-by":"crossref","unstructured":"Kelleni M. Nitazoxanide\/azithromycin combination for COVID-19: a suggested new protocol for early management. Pharmacological Research. 2020;157:104874.","key":"e_1_3_3_98_1","DOI":"10.1016\/j.phrs.2020.104874"},{"doi-asserted-by":"publisher","key":"e_1_3_3_99_1","DOI":"10.1016\/j.jiph.2016.04.001"},{"doi-asserted-by":"publisher","key":"e_1_3_3_100_1","DOI":"10.1186\/s40794-020-00107-1"},{"doi-asserted-by":"crossref","unstructured":"Martin WR Cheng F. Repurposing of FDA-approved toremifene to treat COVID-19 by blocking the spike glycoprotein and NSP14 of SARS-CoV-2. Journal of proteome research. 2020;19(11):4670\u20134677.","key":"e_1_3_3_101_1","DOI":"10.1021\/acs.jproteome.0c00397"},{"doi-asserted-by":"crossref","unstructured":"Maurya VK Kumar S Bhatt ML et\u00a0al. Therapeutic development and drugs for the treatment of COVID-19. Coronavirus disease 2019 (COVID-19). Berlin\/Heidelberg Germany: Springer; 2020. p. 109\u2013126.","key":"e_1_3_3_102_1","DOI":"10.1007\/978-981-15-4814-7_10"},{"unstructured":"Gordon DE Jang GM Bouhaddou M Xu J Obernier K White KM et al. A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature. 2020;583(7816):459\u2013468.","key":"e_1_3_3_103_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_104_1","DOI":"10.1016\/j.diabres.2020.108183"},{"doi-asserted-by":"publisher","key":"e_1_3_3_105_1","DOI":"10.1016\/j.diabres.2020.108230"},{"doi-asserted-by":"publisher","key":"e_1_3_3_106_1","DOI":"10.4269\/ajtmh.20-0375"},{"doi-asserted-by":"publisher","key":"e_1_3_3_107_1","DOI":"10.2139\/ssrn.3612594"},{"key":"e_1_3_3_108_1","first-page":"400","article-title":"Unrevealing sequence and structural features of novel coronavirus using in silico approaches: the main protease as molecular target","volume":"19","author":"Ortega JT","year":"2020","unstructured":"Ortega JT, Serrano ML, Pujol FH, et\u00a0al. Unrevealing sequence and structural features of novel coronavirus using in silico approaches: the main protease as molecular target. EXCLI J. 2020;19:400.","journal-title":"EXCLI J"},{"key":"e_1_3_3_109_1","article-title":"Ensayos clinicos de reposicionamiento de medicamentos Para el tratamiento de la COVID-19","volume":"44","author":"Rosa SGV","year":"2020","unstructured":"Rosa SGV, Santos WC. Ensayos clinicos de reposicionamiento de medicamentos Para el tratamiento de la COVID-19. Rev Panamericana de Salud P\u00fablica. 2020;44.","journal-title":"Rev Panamericana de Salud P\u00fablica"},{"doi-asserted-by":"publisher","key":"e_1_3_3_110_1","DOI":"10.1016\/j.krcp.2015.10.003"},{"doi-asserted-by":"publisher","key":"e_1_3_3_111_1","DOI":"10.1002\/ccr3.106"},{"doi-asserted-by":"publisher","key":"e_1_3_3_112_1","DOI":"10.1136\/adc.2009.160192"},{"doi-asserted-by":"publisher","key":"e_1_3_3_113_1","DOI":"10.1016\/j.addr.2018.04.003"},{"doi-asserted-by":"publisher","key":"e_1_3_3_114_1","DOI":"10.1183\/09031936.00187510"},{"unstructured":"Furrer P. The central role of excipients in drug formulation.\u00a0 European Pharmaceutical Review . 2013.","key":"e_1_3_3_115_1"},{"unstructured":"DailyMed. Glycerin-glycerin suppository. 2020. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=3a59c4a9-5f86-406a-e054-00144ff8d46c.","key":"e_1_3_3_116_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_117_1","DOI":"10.1016\/S0140-6736(87)90117-6"},{"doi-asserted-by":"publisher","key":"e_1_3_3_118_1","DOI":"10.2174\/1381612824666180130121706"},{"doi-asserted-by":"publisher","key":"e_1_3_3_119_1","DOI":"10.1021\/cr500081p"},{"unstructured":"Delivery OD. Combating coronavirus: cyclodextrins in treatment & prevention. 2020.","key":"e_1_3_3_120_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_121_1","DOI":"10.1016\/j.virol.2017.07.024"},{"doi-asserted-by":"publisher","key":"e_1_3_3_122_1","DOI":"10.1128\/JVI.00835-07"},{"doi-asserted-by":"publisher","key":"e_1_3_3_123_1","DOI":"10.1099\/vir.0.070870-0"},{"doi-asserted-by":"publisher","key":"e_1_3_3_124_1","DOI":"10.1016\/j.bbrc.2008.02.023"},{"doi-asserted-by":"publisher","key":"e_1_3_3_125_1","DOI":"10.1016\/j.micinf.2006.10.015"},{"doi-asserted-by":"publisher","key":"e_1_3_3_126_1","DOI":"10.1126\/sciadv.aax9318"},{"doi-asserted-by":"publisher","key":"e_1_3_3_127_1","DOI":"10.1007\/s40121-018-0200-7"},{"doi-asserted-by":"publisher","key":"e_1_3_3_128_1","DOI":"10.1186\/1743-422X-6-124"},{"doi-asserted-by":"publisher","key":"e_1_3_3_129_1","DOI":"10.1016\/j.mehy.2006.07.039"},{"doi-asserted-by":"publisher","key":"e_1_3_3_130_1","DOI":"10.1007\/s40121-018-0202-5"},{"doi-asserted-by":"publisher","key":"e_1_3_3_131_1","DOI":"10.1159\/000089211"},{"unstructured":"Kejner A. COVID-19: povidone-iodine intranasal Prophylaxis In Front-Line Healthcare Personnel and Inpatients (PIIPPI). 2020.","key":"e_1_3_3_132_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_133_1","DOI":"10.1016\/j.ejmech.2015.06.026"},{"unstructured":"Carson D. The Effect of Orally Administered Butylated Hydroxytoluene on Herpes Simplex Keratitis. 1983.","key":"e_1_3_3_134_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_135_1","DOI":"10.1155\/2014\/467452"},{"doi-asserted-by":"publisher","key":"e_1_3_3_136_1","DOI":"10.1159\/000485089"},{"doi-asserted-by":"publisher","key":"e_1_3_3_137_1","DOI":"10.1128\/AAC.8.6.698"},{"doi-asserted-by":"publisher","key":"e_1_3_3_138_1","DOI":"10.1128\/AAC.10.1.96"},{"doi-asserted-by":"publisher","key":"e_1_3_3_139_1","DOI":"10.1016\/j.jhin.2004.12.023"},{"key":"e_1_3_3_140_1","first-page":"03580","article-title":"Mechanisms of viral inactivation methods against hepatitis C virus","volume":"81","author":"Pfaender S","year":"2014","unstructured":"Pfaender S, Brinkmann J, Todt D, et\u00a0al. Mechanisms of viral inactivation methods against hepatitis C virus. Appl Environ Microbiol. 2014;81:03580.","journal-title":"Appl Environ Microbiol"},{"doi-asserted-by":"publisher","key":"e_1_3_3_141_1","DOI":"10.1016\/j.ajic.2009.07.009"},{"doi-asserted-by":"publisher","key":"e_1_3_3_142_1","DOI":"10.1016\/0166-3542(83)90012-8"},{"doi-asserted-by":"publisher","key":"e_1_3_3_143_1","DOI":"10.33425\/2639-944X.1138"},{"doi-asserted-by":"crossref","unstructured":"Mayer F. Perspective: Mouthwash in context with coronavirus. J Med Clin Res Rev. 2020;4(4):1\u20132.","key":"e_1_3_3_144_1","DOI":"10.33425\/2639-944X.1138"},{"doi-asserted-by":"publisher","key":"e_1_3_3_145_1","DOI":"10.1007\/s10517-016-3169-9"},{"doi-asserted-by":"publisher","key":"e_1_3_3_146_1","DOI":"10.3390\/ijms14059906"},{"doi-asserted-by":"publisher","key":"e_1_3_3_147_1","DOI":"10.1111\/lam.12008"},{"issue":"2","key":"e_1_3_3_148_1","first-page":"252","article-title":"Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in\u00a0vitro and in\u00a0vivo","volume":"2","author":"Popkin DL","year":"2017","unstructured":"Popkin DL, Zilka S, Dimaano M, et\u00a0al. Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against influenza viruses in\u00a0vitro and in\u00a0vivo. Pathog Immun. 2017;2(2):252\u2013269.","journal-title":"Pathog Immun"},{"doi-asserted-by":"publisher","key":"e_1_3_3_149_1","DOI":"10.1186\/s12879-016-2177-8"},{"key":"e_1_3_3_150_1","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4049\/jimmunol.50.5.265","article-title":"In vitro and in\u00a0vivo activity of synthetic detergents against influenza a virus","volume":"50","author":"Klein M","year":"1945","unstructured":"Klein M, Stevens DA. In vitro and in\u00a0vivo activity of synthetic detergents against influenza a virus. J Immunol. 1945;50:265\u2013273.","journal-title":"J Immunol"},{"doi-asserted-by":"publisher","key":"e_1_3_3_151_1","DOI":"10.2174\/1389450023348037"},{"doi-asserted-by":"publisher","key":"e_1_3_3_152_1","DOI":"10.1006\/abbi.1999.1267"},{"doi-asserted-by":"publisher","key":"e_1_3_3_153_1","DOI":"10.1128\/JCM.38.1.110-119.2000"},{"key":"e_1_3_3_154_1","first-page":"316","volume-title":"Biosynthesis, genetics and potential applications. Biosurfactants","author":"Sen RS.","year":"2010","unstructured":"Sen RS. Biosynthesis, genetics and potential applications. Biosurfactants. Berlin\/Heidelberg, Germany: Springer; 2010. p. 316\u2013323."},{"doi-asserted-by":"publisher","key":"e_1_3_3_155_1","DOI":"10.1006\/biol.1997.0099"},{"doi-asserted-by":"publisher","key":"e_1_3_3_156_1","DOI":"10.1128\/JVI.00809-18"},{"doi-asserted-by":"publisher","key":"e_1_3_3_157_1","DOI":"10.1016\/B978-0-323-42866-8.00014-9"},{"unstructured":"Holban AM Grumezescu AM. Nanoarchitectonics for smart delivery and drug targeting. Amsterdam Netherlands: William Andrew; 2016.","key":"e_1_3_3_158_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_159_1","DOI":"10.1089\/aid.1992.8.19"},{"doi-asserted-by":"publisher","key":"e_1_3_3_160_1","DOI":"10.1093\/jac\/39.3.339"},{"doi-asserted-by":"publisher","key":"e_1_3_3_161_1","DOI":"10.1128\/AAC.32.11.1742"},{"doi-asserted-by":"publisher","key":"e_1_3_3_162_1","DOI":"10.1016\/j.str.2005.08.021"},{"doi-asserted-by":"publisher","key":"e_1_3_3_163_1","DOI":"10.1016\/j.apsb.2020.04.009"},{"key":"e_1_3_3_164_1","first-page":"159","volume-title":"Heparin and heparan sulfate: analyzing structure and microheterogeneity. Heparin-a century of progress","author":"Shriver Z","year":"2012","unstructured":"Shriver Z, Capila I, Venkataraman G, et\u00a0al. Heparin and heparan sulfate: analyzing structure and microheterogeneity. Heparin-a century of progress. Berlin\/Heidelberg, Germany: Springer; 2012. p. 159\u2013176."},{"doi-asserted-by":"publisher","key":"e_1_3_3_165_1","DOI":"10.1098\/rsif.2015.0589"},{"doi-asserted-by":"publisher","key":"e_1_3_3_166_1","DOI":"10.1016\/0042-6822(92)90680-N"},{"doi-asserted-by":"publisher","key":"e_1_3_3_167_1","DOI":"10.1016\/0042-6822(91)90900-V"},{"doi-asserted-by":"publisher","key":"e_1_3_3_168_1","DOI":"10.1128\/jvi.66.3.1761-1764.1992"},{"doi-asserted-by":"publisher","key":"e_1_3_3_169_1","DOI":"10.3390\/md10122795"},{"doi-asserted-by":"publisher","key":"e_1_3_3_170_1","DOI":"10.1016\/j.virusres.2012.06.025"},{"doi-asserted-by":"publisher","key":"e_1_3_3_171_1","DOI":"10.1073\/pnas.85.16.6132"},{"doi-asserted-by":"publisher","key":"e_1_3_3_172_1","DOI":"10.1021\/bi800205t"},{"doi-asserted-by":"publisher","key":"e_1_3_3_173_1","DOI":"10.1016\/S0306-3623(96)00563-0"},{"doi-asserted-by":"publisher","key":"e_1_3_3_174_1","DOI":"10.1016\/j.bbrc.2008.08.100"},{"doi-asserted-by":"publisher","key":"e_1_3_3_175_1","DOI":"10.1186\/1743-422X-9-307"},{"key":"e_1_3_3_176_1","volume-title":"COVID-19: a recommendation to examine the effect of mouthrinses with \u03b2-cyclodextrin combined with citrox in preventing infection and progression","author":"Carrouel F","year":"2020","unstructured":"Carrouel F, Conte MP, Fisher J, et\u00a0al. COVID-19: a recommendation to examine the effect of mouthrinses with \u03b2-cyclodextrin combined with citrox in preventing infection and progression. Switzerland, Europe: Multidisciplinary Digital Publishing Institute; 2020."},{"doi-asserted-by":"crossref","unstructured":"Kirk-Bayley J Combes J Sunkaraneni S et\u00a0al. The use of povidone iodine nasal spray and mouthwash during the current COVID-19 pandemic may reduce cross infection and protect healthcare workers. Available at SSRN 3563092. 2020.","key":"e_1_3_3_177_1","DOI":"10.2139\/ssrn.3563092"},{"key":"e_1_3_3_178_1","first-page":"7","article-title":"In-situ gel for nasal drug delivery","volume":"8","author":"Mayuri M","year":"2018","unstructured":"Mayuri M, Ban VRC, Dhembre GN, et\u00a0al. In-situ gel for nasal drug delivery. Int J Dev Res. 2018;8:7.","journal-title":"Int J Dev Res"},{"issue":"3","key":"e_1_3_3_179_1","article-title":"Mucoadhesive in situ gels as nasal drug delivery systems: an overview","volume":"7","author":"Swamy N","year":"2012","unstructured":"Swamy N, Abbas Z. Mucoadhesive in situ gels as nasal drug delivery systems: an overview. Asian J Pharm Sci. 2012;7(3).","journal-title":"Asian J Pharm Sci"},{"doi-asserted-by":"publisher","key":"e_1_3_3_180_1","DOI":"10.1016\/j.ijbiomac.2016.02.044"},{"doi-asserted-by":"publisher","key":"e_1_3_3_181_1","DOI":"10.1038\/d41586-020-02544-6"},{"unstructured":"Moses ME. How to fix the vaccine rollout. 2021. Available from: https:\/\/nautilus\/issue\/95\/escape\/how-to-fix-the-vaccine-rollout?mc_cid=2953c1b175&mc_eid=04ac4f97ea","key":"e_1_3_3_182_1"}],"container-title":["Journal of Biomaterials Science, Polymer Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09205063.2021.1975020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T11:40:06Z","timestamp":1707478806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09205063.2021.1975020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,28]]},"references-count":181,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,2]]}},"alternative-id":["10.1080\/09205063.2021.1975020"],"URL":"https:\/\/doi.org\/10.1080\/09205063.2021.1975020","relation":{},"ISSN":["0920-5063","1568-5624"],"issn-type":[{"type":"print","value":"0920-5063"},{"type":"electronic","value":"1568-5624"}],"subject":[],"published":{"date-parts":[[2021,9,28]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tbsp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=tbsp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}